[Federal Register Volume 60, Number 90 (Wednesday, May 10, 1995)]
[Notices]
[Page 24872]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11423]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of Exclusive License: Oncoimmunins
Agency: National Institutes of Health, Public Health Service, DHHS.
Action: Notice.
-----------------------------------------------------------------------
Summary: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(I) that the National Institutes of Health and Human
Services, is contemplating the grant of an exclusive world-wide license
to practice the inventions embodied in a U.S. Patent 5,364,619 and U.S.
Patent Applications; USSN 07/764,695 and USSN 08/218,023 and
corresponding foreign patent applications each entitled,
``Oncoimmunins'' to OncoImmunin, Inc. of Kensington, Maryland. The
patent rights in these inventions have been assigned to the United
States of America.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor
efficacy in both animal and human studies. Functions thought necessary
for antitumor activity include cytolysis, homing, and proliferation at
tumor sites. T-cell mitogens of tumor origin have been suggested to be
responsible, in part, for the local stimulation of T-lymphocytes around
tumors. Two tumor-derived, soluble proteins named Oncoimmunin-L and
Oncoimmunin-M have been isolated and partially characterized.
Oncoimmunin-L is a T-cell mitogen and Oncoimmunin-M is a myeloid
differentiation inducing agent. The partial characterization of these
two factors has shown that they are similar to human leukocyte elastase
inhibitor and human lactate dehydrogenase M, respectively. As cells of
both lymphoid and myeloid origin are known to play roles in immune
defense, factors which can modulate their number and/or function may be
useful in the diagnosis and treatment of cancer. Since these factors
are derived from tumors, their appearance in blood may signal the
presence of tumor or of metastatic disease. The in vivo bioactivities
of these factors suggests their utility as therapeutic agents for
cancer and infectious diseases.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments and other materials relating to the contemplated licenses
should be directed to: Raphe Kantor, Ph.D., Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A
signed Confidentiality Agreement will be required to receive copies of
the patent applications. Applications for a license in any field of use
filed in response to this notice will be treated as objections to the
grant of the contemplated licenses. Only written comments and/or
applications for a license which are received by NIH on or before July
10, 1995 will be considered.
Dated: April 24, 1995.
Maria C. Freire,
Director, Office of Technology Transfer.
[FR Doc. 95-11423 Filed 5-9-95; 8:45 am]
BILLING CODE 4140-01-P
